Skip to main content

Table 3 Treatment terminations for adverse events in original and re-employed methotrexate therapies

From: Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure

   Re-employed course Total
   No adverse event Adverse event  
Original Course No adverse event 45 (13.7 ± 5.2/18.4 ± 5.3) 10 (10.5 ± 3.8/13.5 ± 4.4) 55 (13.1 ± 5.1/17.5 ± 5.5)
  Adverse event 16 (10.2 ± 3.6/14.8 ± 6.3) 8 (8.6 ± 1.3/9.1 ± 2.9) 24 (9.7 ± 3.1/12.9 ± 6.2)
Total 61 (12.8 ± 5.0/17.5 ± 5.7) 18 (9.7 ± 3.2/11.5 ± 4.4) 79 (12.1 ± 4.8/16.1 ± 6.0)
  1. The numbers in parentheses are the doses in the original methotrexate/re-employed methotrexate courses (mean ± standard deviation) in mg/week). The percentage of patients who were concordant for the presence or absence of adverse events was 66.6% (P = 0.327, by McNemar test).